Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6146605 | 0.91 | MAP3K14 (0.30) | MAP3K14 | |
| SCHEMBL4849010 | 0.85 | MAP3K14 (0.36) | MAP3K14 | |
| SCHEMBL4847037 | 0.80 | CYP26A1 (0.46) | — | |
| SCHEMBL6146117 | 0.78 | RARA (0.39) | MAP3K14 | |
| SCHEMBL6146125 | 0.78 | RARA (0.39) | MAP3K14 | |
| SCHEMBL6146120 | 0.78 | RARA (0.39) | MAP3K14 | |
| SCHEMBL4843938 | 0.74 | RARA (0.41) | — | |
| SCHEMBL6144484 | 0.74 | PTGS1 (0.36) | — | |
| SCHEMBL4851072 | 0.73 | HPGD (0.49) | — | |
| SCHEMBL6147976 | 0.72 | UGCG (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354931-B2 | Treating obstructive airway disorders using nontoxic drug | ROCHE PALO ALTO LLC (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1442032-B1 | HETEROCYCLIC RETINOID COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20050049238-A1 | Heterocyclic retinoid compounds | KLAUS MICHAEL (DE) | 2005-03-03 | — | — | US | disclosed |
| US-6818652-B2 | THERAPEUTIC TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CANCER AND DERMATOLOGICAL SKIN DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-16 | — | — | US | disclosed |
| EP-1442032-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030158178-A1 | Heterocyclic retinoid compounds | SYNTEX (U.S.A.) LLC | 2003-08-21 | — | — | US | disclosed |
| WO-2003037882-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049238-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | MAP3K14 4398/4885NR1I2 54/4885 |
| US-20030158178-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | MAP3K14 4398/4885NR1I2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.